DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Safran HP. et al
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: A multicenter randomized phase III trial, NRG Oncology/RTOG 1010..
ASCO 2020 Abstract 4500
Access:
We do not assume any responsibility for the contents of the web pages of other providers.